In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Working Group Talk "RNA-based therapies"

Live Online Event of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine

12/03/2024 15:30 12/03/2024 16:30 Europe/Paris Working Group Talk "RNA-based therapies"

Access event page

ESC Working Group on Cardiovascular Regenerative and Reparative Medicine contact@escardio.org DD/MM/YYYY
Pharmacology and Pharmacotherapy
ESC Working Groups
Online
event

Summary

Nucleotide and in particular RNA-therapeutics are of increasing importance. With Inclisiran (PMID: 27959715), we have a first small interfering RNA (siRNA) therapeutic for the blocking of PCSK9 translation in clinical practice for lowing of LDL-cholesterol. More recently, CRISPR Cas9 encoding RNA with concomitant single guide RNA targeting misfolded transthyretin (TTR) has demonstrated clinical efficacy in patients with TTR amyloidosis (PMID: 34215024). Numerous RNA therapeutics will follow (PMID: 36329321; PMID: 33816449), riding also on the clinical experienced gained from modRNA development for COVID vaccination, because they are easy to develop and can be precisely targeted as highly specific therapies.



Educational goals

- Understand the basics of RNA-based advanced therapeutic medicinal products and their design and manufacturing 
- Be updated on current and future clinical-grade RNA-based therapies 
- Learn about potential applications and challenges for cardiovascular disease

Programme

Chairs 

Wolfram-Hubertus Zimmermann, DE

 

 

Monika Gladka, NL

 

Presentations

The limitless future of RNA therapeutics 

John P. Cooke

John P. Cooke, USA

 

 

Unlocking the promise of mRNA therapeutic

Kenneth Chien, SE

 

 

Questions and Answers

During the Q&A, participants will have the opportunity to interact with the chairs and speaker by asking their questions verbally using the “Raise hand” feature or in written form using the "Q&A" module. Chairs and speaker can answer directly in the module (publicly or privately) or discuss live during the Q&A.

Registration

Registration for this event is free for everyone.

Register

Registration deadline: Tuesday, 12 March at 12:30 CET

The event recording will be accessible on demand a couple of weeks after the live event.